Investing.com - Financial Markets Worldwide

Ilyang Pharmaceutical Co Ltd (007575)

Seoul
Symbol
Exchange
Currency
007575·Seoul·KRW
007570·Seoul·KRW
Currency in KRW
13,860
0(0.00%)
Closed·

007575 Financial Summary

Key Ratios

P/E Ratio21.5
Price/Book1.03
Debt / Equity47.36%
Return on Equity4.8%
Dividend Yield1.26%
EBITDA20.82B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa343,328.72242,511.45247,772.6266,669268,861.23
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa181,638.39104,646.31108,193.71116,403.51111,400.53
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa34,100.8615,188.114,248.9216,379.111,000.5
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa10,879.5814,032.1219,385.18-2,408.6510,257.27
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa439,116.73419,260.64402,916.43392,606.56431,211.15
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa177,147.33167,919.56145,327.72139,262.8156,902
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa244,922.05226,875.84237,784.61230,399.75241,576.31
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa25,856.9934,079.71-1,036.6310,211.38-37,189.72
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa57,484.1951,428.825,883.2714,619.115,614.85
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-21,160.11-14,671.2324,163.02-11,515.54-37,175.26
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-30,961.06-36,632.1-31,996.16-6,978.2232,239.86
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa5,445.5125.49-2,114.5-3,759.31881.17
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 631.30%
Dividend Yield
1.26%
Industry Median 0.93%
Annualised payout
175.00
Paid annually
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
190.00 / --
Revenue / Forecast
61.98B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Ilyang Pharmaceutical Co's earnings for the latest quarter?

The Ilyang Pharmaceutical Co EPS (TTM) is 631.30. Ilyang Pharmaceutical Co reported sales of 61,982.60, net income of 3,537.75, and EPS of 190.00 for the latest quarter.

What was Ilyang Pharmaceutical Co's net income for the latest quarter?

Ilyang Pharmaceutical Co's net income for the latest quarter was 3,537.75.

How did Ilyang Pharmaceutical Co's performance compare year-over-year in the latest quarter?

The company's revenue moved from 8,524.74 in the previous quarter to 61,982.60 in the latest quarter, and net income moved from 3,694.48 to 3,537.75 compared to the previous quarter.

What is Ilyang Pharmaceutical Co's net profit margin on a TTM basis?

Ilyang Pharmaceutical Co's trailing twelve months (TTM) net profit margin is 3.82%.

How does Ilyang Pharmaceutical Co's debt to equity ratio compare to industry standards?

Ilyang Pharmaceutical Co's total debt-to-equity ratio is 47.36%.

What is Ilyang Pharmaceutical Co's return on investment on a TTM basis?

Ilyang Pharmaceutical Co's trailing twelve months (TTM) return on investment (ROI) is 4.80%.

Did Ilyang Pharmaceutical Co gain or lose cash last quarter?

In the latest quarter, Ilyang Pharmaceutical Co's net change in cash was 593.18 million.

What were Ilyang Pharmaceutical Co's total assets and liabilities in the latest quarter?

As of the latest quarter, Ilyang Pharmaceutical Co reported total assets of 437,161.64 million and total liabilities of 153,546.12 million.

How has Ilyang Pharmaceutical Co's total revenue grown this year?

Ilyang Pharmaceutical Co's total revenue was 8,524.74 in the previous quarter and 61,982.60 in the latest quarter.

What is Ilyang Pharmaceutical Co's gross margin on a TTM basis?

Ilyang Pharmaceutical Co's trailing twelve months (TTM) gross margin is 42.01%.

What was Ilyang Pharmaceutical Co's revenue per share for the latest quarter?

Ilyang Pharmaceutical Co's revenue per share for the latest quarter was 14,006.66.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.